Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | recruiting | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07493135 | A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY |
| 1 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) | not yet recruiting | Early Phase 1 | 22 | Shambavi RichardOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06691685 | A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma. | suspended | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07429721 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. | recruiting | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04504526 | Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases | recruiting | Early Phase 1 | 50 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07101705 | An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies | recruiting | Early Phase 1 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02603887 | Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06636175 | 64Cu-LLP2A for Imaging Hematologic Malignancies | recruiting | Early Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07628595 | Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 19 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04211259 | Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization | recruiting | Early Phase 1 | 70 | Rutgers, The State University of New JerseyOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07577206 | Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia. | recruiting | Early Phase 1 | 10 | National Cancer Institute, NaplesOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06663046 | Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma | suspended | Early Phase 1 | 30 | Wondercel Biotech (ShenZhen)INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT07539233 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. | not yet recruiting | Early Phase 1 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06385652 | PET Imaging Study of 68Ga-NB381 in Multiple Myeloma | recruiting | Early Phase 1 | 30 | Peking University First HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06142396 | Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure | recruiting | Early Phase 1 | 30 | Augusta UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(CART-BCMA) | not yet recruiting | Early Phase 1 | 3 | Chulalongkorn UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07234721 | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma(SL4903) | not yet recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07399444 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）(LB2505-0001) | not yet recruiting | Early Phase 1 | 38 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05093335 | In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT01269593 | PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | active not recruiting | Early Phase 1 | 63 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07336823 | JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 9 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07322159 | IASO206 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 7, 2026 | clinicaltrials |
| NCT04370483 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 1 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05560399 | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma(CC-220) | active not recruiting | Early Phase 1 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03631043 | Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | completed | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07249073 | CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07185477 | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma(QLS32015) | not yet recruiting | Early Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT04862676 | Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT | completed | Early Phase 1 | 29 | University of RochesterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07085559 | Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research | recruiting | Early Phase 1 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06976437 | A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors | recruiting | Early Phase 1 | 21 | YANRU WANGOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06717113 | A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma | recruiting | Early Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06999031 | A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05846880 | VitD3 Supplementation in Patients With Multiple Myeloma | recruiting | Early Phase 1 | 100 | Amany Keruakous, MD, MS.OTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06791681 | A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma | recruiting | Early Phase 1 | 24 | Chunrui LiOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06209606 | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | recruiting | Early Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06732232 | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | terminated | Early Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06407947 | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma | recruiting | Early Phase 1 | 10 | Shanghai Changzheng HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06379451 | An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma | unknown | Early Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT05013437 | Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma(AHCT) | withdrawn | Early Phase 1 | 0 | Koen van BesienOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05840107 | Study of FasT CAR-T GC012F Injection NDMM Patients | unknown | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05643248 | To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects | completed | Early Phase 1 | 9 | Nanexa ABINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials